Host-defence caerin 1.1 and 1.9 peptides suppress glioblastoma U87 and U118 cell proliferation through the modulation of mitochondrial respiration and induce the downregulation of CHI3L1.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Glioblastoma*/metabolism ; Glioblastoma*/pathology ; Cell Proliferation*/drug effects ; Mitochondria*/metabolism ; Mitochondria*/drug effects ; Down-Regulation*/drug effects; Humans ; Cell Line, Tumor ; Cell Respiration/drug effects ; Animals ; Brain Neoplasms/metabolism ; Brain Neoplasms/pathology ; Antimicrobial Cationic Peptides/pharmacology ; Antimicrobial Cationic Peptides/metabolism ; Cell Movement/drug effects

Glioblastoma, the most aggressive form of brain cancer, poses a significant global health challenge with a considerable mortality rate. With the predicted increase in glioblastoma incidence, there is an urgent need for more effective treatment strategies. In this study, we explore the potential of caerin 1.1 and 1.9, host defence peptides derived from an Australian tree frog, in inhibiting glioblastoma U87 and U118 cell growth. Our findings demonstrate the inhibitory impact of caerin 1.1 and 1.9 on cell growth through CCK8 assays. Additionally, these peptides effectively curtail the migration of glioblastoma cells in a cell scratch assay, exhibiting varying inhibitory effects among different cell lines. Notably, the peptides hinder the G0/S phase replication in both U87 and U118 cells, pointing to their impact on the cell cycle. Furthermore, caerin 1.1 and 1.9 show the ability to enter the cytoplasm of glioblastoma cells, influencing the morphology of mitochondria. Proteomics experiments reveal intriguing insights, with a decrease in CHI3L1 expression and an increase in PZP and JUNB expression after peptide treatment. These proteins play roles in cell energy metabolism and inflammatory response, suggesting a multifaceted impact on glioblastoma cells. In conclusion, our study underscores the substantial anticancer potential of caerin 1.1 and 1.9 against glioblastoma cells. These findings propose the peptides as promising candidates for further exploration in the realm of glioblastoma management, offering new avenues for developing effective treatment strategies.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Drug Discov Today. 2019 May;24(5):1193-1201. (PMID: 30878561)
Front Immunol. 2018 Dec 21;9:2924. (PMID: 30619286)
Chem Pharm Bull (Tokyo). 2020;68(4):316-325. (PMID: 32238649)
BioDrugs. 2023 Sep;37(5):607-623. (PMID: 37300748)
Front Hum Neurosci. 2021 Feb 03;14:609080. (PMID: 33613204)
Cancers (Basel). 2022 Nov 24;14(23):. (PMID: 36497272)
Diagn Pathol. 2016 Apr 27;11:42. (PMID: 27121858)
Toxicol Appl Pharmacol. 2006 Sep 1;215(2):208-17. (PMID: 16580038)
Front Oncol. 2021 Nov 11;11:754770. (PMID: 34858827)
Clin Cancer Res. 2014 May 15;20(10):2684-94. (PMID: 24658154)
Curr Cancer Drug Targets. 2021;21(11):932-943. (PMID: 34732116)
Am J Respir Crit Care Med. 2019 Oct 15;200(8):992-1001. (PMID: 31264895)
Microbiol Spectr. 2021 Sep 3;9(1):e0005121. (PMID: 34259550)
Nat Immunol. 2019 Sep;20(9):1100-1109. (PMID: 31358997)
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52. (PMID: 25352553)
Int J Mol Sci. 2022 Dec 09;23(24):. (PMID: 36555253)
FEBS Open Bio. 2021 Mar;11(3):826-832. (PMID: 33471436)
BMJ. 2021 Jul 14;374:n1560. (PMID: 34261630)
Signal Transduct Target Ther. 2020 Sep 14;5(1):201. (PMID: 32929074)
Front Cell Dev Biol. 2020 Jul 31;8:676. (PMID: 32850805)
J Control Release. 2018 Jan 28;270:290-303. (PMID: 29269142)
Cancer Res. 1988 Sep 15;48(18):5183-7. (PMID: 3409244)
Biomed Res Int. 2022 Apr 11;2022:7841219. (PMID: 35445137)
Front Immunol. 2018 May 08;9:1004. (PMID: 29867979)
Mol Oncol. 2022 Jun;16(11):2214-2234. (PMID: 34861103)
Immunol Res. 2013 Dec;57(1-3):99-105. (PMID: 24222276)
Biochem Soc Trans. 2019 Apr 30;47(2):625-638. (PMID: 30902924)
Nat Rev Cancer. 2020 Jan;20(1):12-25. (PMID: 31806885)
Front Immunol. 2020 Jul 17;11:1402. (PMID: 32765498)
BMC Complement Altern Med. 2019 Jul 6;19(1):163. (PMID: 31277636)
Pharmacol Ther. 2019 Nov;203:107394. (PMID: 31356910)
Cells. 2023 Feb 14;12(4):. (PMID: 36831285)
Pharmacol Res. 2021 Sep;171:105780. (PMID: 34302977)
Drug Deliv Transl Res. 2021 Dec;11(6):2302-2316. (PMID: 34053034)
J Neurooncol. 2017 Jan;131(1):1-9. (PMID: 27743144)
CNS Drugs. 2020 Nov;34(11):1121-1131. (PMID: 32965590)
Breast Cancer Res Treat. 2021 Jan;185(2):317-330. (PMID: 33057846)
Commun Biol. 2019 Aug 19;2:315. (PMID: 31453379)
Int J Cancer. 2011 Mar 15;128(6):1316-26. (PMID: 20506295)
Biochem Biophys Res Commun. 2012 May 18;421(4):790-6. (PMID: 22554524)
Nat Genet. 2003 Jul;34(3):267-73. (PMID: 12808457)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Semin Oncol Nurs. 2004 Nov;20(4):273-83. (PMID: 15612603)
J Mater Chem B. 2021 Aug 21;9(31):6103-6115. (PMID: 34259709)
J Proteome Res. 2011 Jul 1;10(7):3149-59. (PMID: 21574646)
Cell Immunol. 2004 Nov-Dec;232(1-2):144-56. (PMID: 15882859)
Theranostics. 2022 Oct 03;12(16):6989-7008. (PMID: 36276655)
Biomedicines. 2023 Jul 13;11(7):. (PMID: 37509617)
Biochim Biophys Acta. 2011 Jun;1807(6):552-61. (PMID: 20955683)
Microbiol Spectr. 2023 Dec 12;11(6):e0452022. (PMID: 37819110)
Oncogene. 1997 Apr 10;14(14):1635-42. (PMID: 9135064)
Nat Methods. 2009 May;6(5):359-62. (PMID: 19377485)
Cancer Manag Res. 2020 Oct 09;12:9883-9891. (PMID: 33116846)
Int J Biol Sci. 2012;8(1):39-48. (PMID: 22211103)
Clin Cancer Res. 2005 May 1;11(9):3326-34. (PMID: 15867231)
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. (PMID: 34723319)
Nucleic Acids Res. 2000 Jan 1;28(1):27-30. (PMID: 10592173)
Clin Transl Immunology. 2021 Aug 17;10(8):e1335. (PMID: 34429969)
Biomed Res Int. 2018 May 13;2018:7382351. (PMID: 29862288)
Pharm Res. 2007 Sep;24(9):1745-58. (PMID: 17619998)
Nat Commun. 2019 Jun 11;10(1):2541. (PMID: 31186414)
Oxid Med Cell Longev. 2019 Jul 22;2019:5410657. (PMID: 31428227)
Immunotherapy. 2014;6(6):679-90. (PMID: 25186601)
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. (PMID: 32442275)
Cancer Lett. 2018 Aug 10;429:54-65. (PMID: 29729901)

0 (Antimicrobial Cationic Peptides)

Date Created: 20240607 Date Completed: 20240607 Latest Revision: 20240610

20240610

PMC11161062

10.1371/journal.pone.0304149

38848430